Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The phosphoinositide 3-kinase (PI3K) pathway is crucial in cancer, but PI3K inhibitors show limited efficacy.
• Feedback loops within the PI3K pathway contribute to drug resistance and reduced therapeutic activity.

Purpose of the Study:

• To comprehensively characterize PI3K pathway signaling mechanisms in bladder cancer.
• To identify molecular targets and feedback loops limiting the effectiveness of PI3K pathway inhibitors.
• To develop improved combination strategies for cancer therapy.

Main Methods:

• Utilized small molecule inhibitors and RNA interference (RNAi) targeting key PI3K pathway molecules.
• Analyzed molecular and functional consequences of pathway inhibition in bladder cancer cell lines.
• Investigated feedback mechanisms, including AKT rephosphorylation, in response to long-term PI3K inhibition.

Main Results:

• Inhibition of single pathway components (mTORC1, mTOR, AKT, PI3K) primarily affected S6K1 phosphorylation.
• 4E-BP1 dephosphorylation and significant cell viability reduction required combined PI3K and mTORC1 inhibition.
• Long-term PI3K inhibition led to AKT rephosphorylation, dependent on PDK1 but independent of PIP3 and mTORC2.
• Combined inhibition of PI3K/mTOR with AKT or PDK1 inhibitors suppressed AKT rephosphorylation and induced apoptosis.

Conclusions:

• Novel feedback mechanisms, including PDK1-dependent AKT rephosphorylation, limit the efficacy of single-agent PI3K pathway inhibitors.
• Simultaneous targeting of PI3K, AKT, and mTORC1 is required for effective inhibition of tumor growth.
• These findings provide a rationale for combination therapies in bladder cancer and potentially other malignancies driven by the PI3K pathway.